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Strengths and limitations of this study
 ► The present systematic review will be based on a 
systematic and thorough search of literature inde-
pendently performed by two reviewers concordant 
with the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines, hereby in-
creasing the generalisability and reliability of the 
findings.
 ► The scientific quality of each reviewed study will be 
assessed by use of standardised quality assessment 
tools and only the content of peer- reviewed original 
research papers will be included in the analysis.
 ► Only English language studies will be included in the 
systematic review.
AbStrACt
Introduction The term defensive medicine, referring 
to actions motivated primarily by litigious concerns, 
originates from the USA and has been used in medical 
research literature since the late 1960s. Differences in 
medical legal systems between the US and most European 
countries with no tort legislation raise the question 
whether the US definition of defensive medicine holds true 
in Europe.
Aim To present the protocol of a systematic review 
investigating variations in definitions and understandings 
of the term ‘defensive medicine’ in European research 
articles.
Methods and analysis In concordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses guidelines, a systematic review of all 
medical research literature that investigate defensive 
medicine will be performed by two independent reviewers. 
The databases PubMed, Embase and Cochrane will be 
systematically searched on the basis of predetermined 
criteria. Data from all included European studies will 
systematically be extracted including the studies’ 
definitions and understandings of defensive medicine, 
especially the motives for doing medical actions that the 
study regards as ‘defensive’.
Ethics and dissemination No ethics clearance is 
required as no primary data will be collected. The results 
of the systematic review will be published in a peer- 
reviewed, international journal.
PrOSPErO registration number This review has 
been submitted to International Prospective Register 
of Systematic Reviews (PROSPERO) and is awaiting 
registration.
IntrOduCtIOn
background
Defensive medicine (DM) is a term that has 
been used in the medical research literature 
since the late 1960s.1 The term originates 
from the US2 and has since then taken on 
various connotations.3 The most commonly 
used definition describes DM as ‘physicians’ 
deviations from sound medical practice due 
to fear of liability claims and lawsuits’.4–8 DM 
can additionally be subdivided into two main 
forms of behaviour: (1) positive DM (also 
labelled active DM or assurance behaviour), 
which involves physicians ordering extra 
diagnostic tests, procedures or visits and (2) 
negative DM (also labelled passive DM or 
avoidance behaviour) which is the avoidance 
of high- risk patients or procedures. Both 
forms aim to reduce physicians’ exposure to 
malpractice liability.4–7 The above definition 
of DM consists of two components: A medical 
action and an underlying motive for acting 
defensively.
DM has been associated with rising health-
care costs.7 Furthermore, it has been associ-
ated with overtreatment, overprescription 
and overdiagnosing of patients and decreased 
trust in the physician–patient relationship, 
leading patients to mistrust physicians’ moti-
vations and physicians to regard patients as 
potential plaintiffs.7 9–12 Moreover, physicians 
report patient disrespect for their profession-
alism, personal frustration and inequality 
in healthcare as possible consequences of 
DM.13 14
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In the USA, DM is reported to be frequent.15 The 
number of lawsuits for medical malpractice has risen 
significantly,9 and DM has been shown to be directly 
related to this growth.12 US physicians are forced to hold 
expensive malpractice insurances in order to cover the 
cost from malpractice suits.16 Hence, with inadequate 
legislation protecting physicians from tort, concerns 
about malpractice liability is likely to be the predominant 
reason to act defensively.7 Indeed, negative associations 
have been found between physicians’ use of medical 
resources and risk of malpractice claims.17
In several European countries malpractice litigation is 
reported to happen less frequently than in the USA, for 
example in The Netherlands,2 18 Denmark,13 Switzerland19 
and the UK.20 In these countries, the medicolegal system 
does not hold physicians financially liable for malpractice 
or other treatment related adverse events. The patients 
are instead compensated by the government (known as 
a no- fault system).21–23 Nevertheless, DM seems also to be 
prevalent in Europe, for example Denmark,13 the UK,24 
Italy,12 Belgium,25 The Netherlands,2 Germany26 and Swit-
zerland.20 Furthermore, a substantial part of research on 
DM seems to originate from Europe.
Variations in medicolegal systems between the US and 
most European countries raise the question whether the 
definition of DM, as actions motivated primarily by liti-
gious concerns, holds true in European countries where 
physicians are not subjected to tort legislation20 and if 
other motives for performing defensive medical actions 
are documented in the European literature on DM.27
rationale
Science needs definitions. To our knowledge no system-
atic review exists of how DM is defined and understood in 
the European scientific, medical literature. A systematic 
review of the term ‘defensive medicine’ in the European 
context will provide a more nuanced understanding of 
this complex and non- beneficial phenomenon, hereby 
supporting the quality of future research on the topic.
Objectives
The aim of this study is to present a protocol paper for a 
systematic review with the following objective: To analyse 
variations in the definitions and understandings of the 
term ‘defensive medicine’ in European research articles.
MEthOdS
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting, or dissemination of our research.
Protocol
This protocol for a systematic review is conducted in 
concordance with the PRISMA Protocol.28
Eligibility criteria
Publications will be included in the review based on the 
following criteria.
Inclusion criteria
1. One or both of the terms ‘defensive medicine’ and ‘de-
fensive practice’ are stated in title or abstract.
2. The study is available in full text and written in English 
language.
3. DM is performed by physicians, including general 
practitioners, as well as physicians from medical, surgi-
cal and paraclinical specialities.
4. The study is an original research study (quantitative 
or qualitative primary research) or systematic review 
published in a peer- reviewed, medical journal.
5. DM is stated as part of the study’s aim/objective in at 
least one of the following ways:
a. DM is included in the publication’s aim/objective.
b. DM is implicitly a significant part of the aim/objec-
tive.
Further
6. The study’s research data includes data from Europe.
Information sources
Eligible studies will be searched in three databases: 
PubMed, Embase and Cochrane from conception to 
February 3rd 2020.
Search strategy
The preparation of search strategy is based on the original 
American term ‘defensive medicine’. In accordance with 
the database PubMed, the MeSH term ‘defensive medi-
cine’ is combined with the entry terms ‘defensive prac-
tice’, ‘defensive practices’ and ‘medicine, defensive’. On 
the basis of this, the following search strategy will be used: 
‘defensive medicine OR defensive practice OR defensive 
practices OR medicine, defensive’. All references in the 
papers fulfilling the inclusion criteria will be examined 
in order to identify potentially neglected studies. The 
literature search will be updated before the final analysis. 
See online supplementary appendix for detailed search 
strategy.
Study records
Data management
Publications found by the search strategy will be exported 
into the reference management software (EndNote)29 and 
the software Covidence,30 where the systematic screening 
and data extraction will be performed, including the 
removing of duplicates. Number of citations for each 
study will be assessed with Web of Science31 in concor-
dance with the PRISMA guidelines.28
Selection process
Two independent reviewers (NB and PS) will screen 
all potentially relevant studies in a two- phase screening 
process to ensure interrater reliability, compliance with 
the inclusion criteria and eligibility by use of Covidence.30 
NB and PS will discuss and resolve any disagreements to 
reach consensus. If consensus is not achievable, a third 
reviewer (JL) will be involved in the discussion and finally 
decide whether the study in question is to be included or 
not.
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Data collection process
The primary authors (NB and PS) will extract data 
from the included studies, including publication details 
(author(s), name of journal, year of publication), study 
characteristics (design, country of origin, sample size, 
medical specialty investigated and number of citations), 
study objective, stated definitions of DM and understand-
ings of DM.
Quality assessment
The two reviewers (NB and PS) will independently assess 
the quality of each study. The qualitative studies will be 
reviewed using the Critical Appraisal Skills Programme,32 
recommended by the Centre for Clinical Guidelines 
(CFKR),33 to ensure a critical and standardised assessment 
of the quality and analysis of the study. The quantitative 
studies will be reviewed using a cross- sectional appraisal 
tool with questions adapted from Guyatt et al. JAMA 1993 
and 1994.34 35 The systematic reviews will be reviewed 
using Assessing the Methodological Quality of Systematic 
Reviews36 recommended by the CFKR.33 Disagreements 
will be discussed until consensus is reached.
data items
Data items are as stated above under ‘methods’. The 
design of the review is based on the hypothesis that a defi-
nition of DM reflects the medicolegal system in which it 
is used. Therefore, we expect the definitions and under-
standings of DM stated in the European research liter-
ature to be different than those stated in the literature 
deriving from the USA.
data synthesis
For each paper, the stated definition and understanding 
of DM will be extracted by the first author (NB). The 
definition of DM will be identified as: ‘DM is…’, ‘DM is 
defined as…’, ‘DM refers to…’, or ‘DM is characterised 
by…’. If no definition of DM is stated, the way in which 
DM is introduced will be identified. A paper’s under-
standing of DM is assessed from its use in the study and 
may differ from the stated definition. Quotes identifying 
how DM is understood will be extracted and analysed 
according to a thematic analysis approach aiming to cate-
gorise the different understandings. Based on the above 
definitions of DM, it is expected that the vast majority of 
papers will define DM as healthcare actions conducted by 
healthcare professionals during their work, but that the 
motives making the actions defensive may differ between 
papers showing a broader understanding of DM in some 
European studies than according to the US definition. 
Thus, for each paper, the motives regarded as defensive 
will be identified in the texts, tables, figures, as well as in 
the data collection methods. The identified categories of 
DM definitions and understandings will be scrutinised by 
the author group.
Outcomes and prioritisation
The review’s main outcomes will be a categorisation of 
the identified definitions of DM in the European medical 
research literature focusing on the motives for medical 
acting that the studies regard as defensive and a graphical 
display of the historical trend in the annual number of 
published European original research papers regarding 
DM divided on the identified categories of DM defini-
tions. The review will report if any differences in the defi-
nitions and understandings of DM between countries and 
between high- quality and low- quality papers exist.
risk of bias in individual studies
Since the objective of this study differs from most system-
atic reviews by not taking interest in the results found by 
the reviewed studies, the quality assessment of the iden-
tified papers serves a different purpose. The assessment 
of the quality of the papers is used to show whether high 
quality papers use a different definition of DM than 
other papers (see the above- described quality assessment 
procedure).
Although there are multiple languages used in Europe, 
the review only includes English scientific literature. 
However, most high- ranking scientific journals reporting 
on DM is written in English and we specifically aim to 
support future research on DM. Furthermore, DM was 
originally conceptualised in English.
COnCluSIOn
This systematic review will address the variations in the 
definitions and understandings of the term ‘defensive 
medicine’ in European research articles. This review 
seeks to provide a more nuanced understanding of the 
complex and non- beneficial phenomenon of DM, hereby 
supporting the quality of future research on the topic.
Potential amendments
We do not envisage any amendments to the present 
protocol. However, should an amendment be necessary, 
it will be notified, registered and reported.
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